We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-8.66%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$419M
AUM Growth
-$20.7M
Cap. Flow
+$25.1M
Cap. Flow %
5.99%
Top 10 Hldgs %
47.79%
Holding
85
New
13
Increased
17
Reduced
18
Closed
2

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$8.5M
2
URGN icon
UroGen Pharma
URGN
+$6.67M
3
BHVN icon
Biohaven
BHVN
+$3.95M
4
ALKS icon
Alkermes
ALKS
+$2.96M
5
SLRN
ACELYRIN
SLRN
+$2.3M

Top Sells

Rank Stock Value
1
PRCT icon
Procept Biorobotics
PRCT
+$2.44M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$2.25M
3
BNTX icon
BioNTech
BNTX
+$1.57M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.56M
5
CATX icon
Perspective Therapeutics
CATX
+$1.14M

Sector Composition

Rank Sector Weight
1 Healthcare 85.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
51
Mineralys Therapeutics
MLYS
$2.27B
$1.39M 0.33%
119,000
+29,000
+32% +$365K
AQST icon
52
Aquestive Therapeutics
AQST
$476M
$1.38M 0.33%
530,000
+30,000
+6% +$100K
LCTX icon
53
Lineage Cell Therapeutics
LCTX
$277M
$1.35M 0.32%
1,350,708
-15,600
-1% -$17.2K
ANRO icon
54
Alto Neuroscience
ANRO
$1.06B
$1.28M 0.31%
120,000
+110,000
+1,100% +$1.43M
GOSS icon
55
Gossamer Bio
GOSS
$84.9M
$1.27M 0.3%
1,409,262
– –
IMVT icon
56
Immunovant
IMVT
$7.91B
$1.26M 0.3%
47,916
+18,500
+63% +$526K
SAGE
57
DELISTED
Sage Therapeutics
SAGE
$1.26M 0.3%
+116,200
New +$1.49M
AUTL
58
Autolus Therapeutics
AUTL
$484M
$1.21M 0.29%
346,667
+130,000
+60% +$561K
CNTA
59
DELISTED
Centessa Pharmaceuticals
CNTA
$1.11M 0.27%
+122,882
New +$1.17M
TRML
60
DELISTED
Tourmaline Bio
TRML
$977K 0.23%
+75,982
New +$1.22M
STRO icon
61
Sutro Biopharma
STRO
$416M
$966K 0.23%
32,958
-450
-1% -$17.8K
PRCT icon
62
Procept Biorobotics
PRCT
$1.05B
$855K 0.2%
13,994
-41,001
-75% -$2.44M
PYPD icon
63
PolyPid
PYPD
$83.6M
$795K 0.19%
184,846
-600
-0.3% -$2.68K
CGEN icon
64
Compugen
CGEN
$225M
$776K 0.19%
462,202
+32,000
+7% +$66.7K
NYXH
65
Nyxoah
NYXH
$146M
$754K 0.18%
+108,108
New +$1.03M
ACET icon
66
Adicet Bio
ACET
$86.4M
$726K 0.17%
37,500
– –
ACRV icon
67
Acrivon Therapeutics
ACRV
$66.8M
$704K 0.17%
121,351
-10,000
-8% -$80.5K
SYRS
68
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$701K 0.17%
135,850
– –
ADCT icon
69
ADC Therapeutics
ADCT
$134M
$645K 0.15%
+204,081
New +$811K
TERN
70
DELISTED
Terns Pharmaceuticals
TERN
$586K 0.14%
+86,000
New +$521K
STIM icon
71
Neuronetics
STIM
$150M
$565K 0.13%
313,717
– –
APRE icon
72
Aprea Therapeutics
APRE
$7.4M
$558K 0.13%
137,174
– –
NGNE icon
73
Neurogene
NGNE
$656M
$400K 0.1%
+11,000
New +$388K
MASI
74
DELISTED
Masimo
MASI
$378K 0.09%
3,000
– –
ADAP
75
DELISTED
Adaptimmune Therapeutics
ADAP
$333K 0.08%
341,064
– –
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, DAFNA Capital Management held 85 positions worth $419M, down 4.7% from $439M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $25.1M of net new capital in Q2 2024, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was UroGen Pharma: 469,000 shares worth $7.87M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Procept Biorobotics, an estimated $2.44M trimmed.

  • DAFNA Capital Management's largest Q2 2024 buy was UroGen Pharma: 469,000 shares worth $7.87M.
  • DAFNA Capital Management added most to AtriCure in Q2 2024, an estimated $8.5M increase.
  • DAFNA Capital Management's biggest Q2 2024 reduction was Procept Biorobotics, cutting an estimated $2.44M.
  • DAFNA Capital Management fully exited BioNTech in Q2 2024, selling an estimated $1.57M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $419M portfolio in Q2 2024.
  • DAFNA Capital Management opened 13 new positions and closed 2 in Q2 2024.
  • DAFNA Capital Management's portfolio value fell 4.7% quarter-over-quarter to $419M.

Based on DAFNA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.